Scinai Immunotherapeutics Ltd. financial data

Symbol
SCNI on Nasdaq
Location
Jerusalem Biopark, 2 Nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel
Fiscal year end
December 31
Latest financial report
20-F - Q4 2024 - May 7, 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.41B shares +83.7%
Common Stock, Shares, Outstanding 6.06B shares +80.8%
Weighted Average Number of Shares Outstanding, Basic 1.35B shares +81%
Weighted Average Number of Shares Outstanding, Diluted 1.35B shares +81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.45M USD -26.3%
General and Administrative Expense 1.14M USD -11.5%
Operating Income (Loss) -2.6M USD +20.5%
Nonoperating Income (Expense) -1.17M USD -517%
Net Income (Loss) Attributable to Parent -3.76M USD -26.1%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 989K USD -67.8%
Accounts Receivable, after Allowance for Credit Loss, Current 139K USD +16.8%
Other Assets, Current 437K USD +182%
Assets, Current 1.51M USD -58.8%
Property, Plant and Equipment, Net 8.5M USD -16.5%
Operating Lease, Right-of-Use Asset 1.84M USD +81.2%
Assets 11.8M USD -20.3%
Employee-related Liabilities, Current 254K USD -34.5%
Accrued Liabilities, Current 527K USD +14.3%
Liabilities, Current 2.12M USD +26.8%
Operating Lease, Liability, Noncurrent 1.57M USD +145%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.74M USD 0%
Retained Earnings (Accumulated Deficit) -122M USD +4.06%
Stockholders' Equity Attributable to Parent 7.86M USD
Liabilities and Equity 11.8M USD -20.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06M USD -177%
Net Cash Provided by (Used in) Investing Activities -6K USD +98.8%
Common Stock, Shares Authorized 40B shares +100%
Common Stock, Shares, Issued 6.06B shares +80.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.29M USD -65.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.13M USD -64.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 725K USD
Deferred Tax Assets, Valuation Allowance 23.7M USD -10.3%
Operating Lease, Liability 1.83M USD
Payments to Acquire Property, Plant, and Equipment 6K USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3.61M USD
Lessee, Operating Lease, Liability, to be Paid 3.11M USD
Property, Plant and Equipment, Gross 13.6M USD +121%
Operating Lease, Liability, Current 497K USD +36.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 384K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 426K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.29M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 384K USD
Deferred Tax Assets, Operating Loss Carryforwards 23.4M USD -10.5%
Preferred Stock, Shares Issued 1K shares
Preferred Stock, Shares Authorized 1K shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 384K USD
Additional Paid in Capital 126M USD +3.61%
Preferred Stock, Shares Outstanding 1K shares
Depreciation, Depletion and Amortization 138K USD +2.99%
Deferred Tax Assets, Net of Valuation Allowance 23.4M USD -10.6%
Share-based Payment Arrangement, Expense 252K USD -48%